Tuesday, September 26th

Program Schedule

Click on session titles for details

MEETING WORKSHOP: NK Cells in the Clinic

Start End Session Location
09:00 10:20 Saga Hall
Moderators: Hans-Gustaf Ljunggren, Karolinska Institutet
Katy Rezvani, MD Anderson Cancer Center
Todd Fehniger, Washington University School of Medicine
Memory-like NK cell biology and cancer immunotherapy
Katy Rezvani, MD Anderson Cancer Center
State of off-the-shelf cellular therapies in the clinic: Engineering NK cells for cancer immunotherapy
Dean Lee, Nationwide Children's Hospital
Implementation of universal donor sourcing for NK cell clinical trials
Jeffrey Miller, University of Minnesota
To be announced
10:20 11:00 Coffee Break Foyer
11:00 12:00 Saga Hall
Moderators: Aharon Freud, The Ohio State University
Ebba Sohlberg, Karolinska Institutet
Salim Khakoo, University of Southampton
Exportin-1 (XPO-1) as a target for natural killer cells in hepatocellular carcinoma
Michal Sheffer, Dana-Farber Cancer Institute
Cellular therapy of cytokine induced memory-like NK cells for the treatment of head and neck cancer
Erin Jeremy, The Ohio State University
The role of persistent AP-1 activation in NK cell exhaustion programming in AML
Sunil Acharya, MD Anderson Cancer Center
Generation and screening of various CD70 CAR NK cells identify the most effective construct against hematologic malignancies
Veronika Bachanova, University Of Minnesota
Allogeneic NK Cell Therapy for Lymphoma Revealed Cross-Talk with Adaptive T-Cell Immunity: Insights from Tumor Microenvironment Spatial Analysis
Jiri Eitler, Technische Universität Dresden
Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss
12:00 13:30 Lunch (Hosted by NextGenNK) Restaurant
13:30 14:30 Saga Hall
Moderators: Rizwan Romee, Dana-Farber Cancer Institute
Veronika Bachanova, University of Minnesota
Dan Kaufman, University of California San Diego
Development of drug resistant NK cells for improved anti-tumor activity
Ulrike Kohl, Fraunhofer Institut für Zelltherapie und Immunologie (IZI)
From CAR T to CAR NK cells: Pushing the boundaries in cancer treatment and beyond
Erik Vivier, Centre d’Immunologie de Marseille-Luminy (CIML)
Harnessing NK cell immunity in cancer therapies
14:30 15:15 Saga Hall
Moderators: Rizwan Romee, Dana-Farber Cancer Institute
Evren Alici, Karolinska Institutet
Sarah Cooley, Sanofi
15:15 16:00 Closing of Workshop. Coffee and refreshments Foyer
16:00 17:00 Saga Hall
Karl-Johan Malmberg, University of Oslo
Welcome to NK2023!
Lewis Lanier, University of California San Francisco
Natural Killer cells – a 4-decade Quest
17:00 17:30 Saga Hall
Moderators: Erik Dissen, University of Oslo
Jakob Michaelsson, Karolinska Institutet
Olli Dufva, University of Helsinki
Single-cell functional genomics of natural killer cell evasion in blood cancers
Arman Bashirova, Leidos Biomedical Research
HLA class I signal peptide polymorphism: impact on HLA-E-mediated regulation of NK and T cells
Sytse Piersma, Washington University in St Louis
HuR-dependent NK cell expansion mediate control of primary tumors without affecting clearance of tumor metastases.
Linnea Kristen, University of Gothenburg
Deletion of the TMEM30A gene allows leukemic cell evasion of NK cell cytotoxicity
Tobias Bexte, University Hospital Frankfurt
CRISPR/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-directed CAR-NK cells
May Daher, MD Anderson Cancer Center
Crosstalk between NK cells and myeloid blasts leads to an epigenetic state of exhaustion
18:00 19:30 Reception Restaurant
19:30 21:00 Poster Session 1, A001-A130 Poster Area

Gold Sponsors

Vycellix Logo
Fate Logo
Sanofi Logo

Silver Sponsors

ScaleReady Logo
MaxCyte Logo

Bronze Sponsors

Zelluna Logo
XNK Logo
Miltenyi Logo
Innate Pharma logo
Oncopeptides Logo
Affimed Logo
ImmuneBridge Logo
CellGenix Logo
Cellmover Logo

Academic Partners

SJI Logo
NextGenNK Logo
Prima Logo
UiO Logo
OUS Logo